2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Sodium Channel

Sodium Channel

Na channels; Na+ channels

Sodium Channel

Related Products

PDF 3.33 MB

Sodium channels are integral membrane proteins that form ion channels, conducting sodium ions (Na+) through a cell's plasma membrane. They are classified according to the trigger that opens the channel for such ions, i.e. either a voltage-change (Voltage-gated, voltage-sensitive, or voltage-dependent sodium channel also called VGSCs or Nav channel) or a binding of a substance (a ligand) to the channel (ligand-gated sodium channels). In excitable cells such as neurons, myocytes, and certain types of glia, sodium channels are responsible for the rising phase of action potentials. Voltage-gated Na+ channels can exist in any of three distinct states: deactivated (closed), activated (open), or inactivated (closed). Ligand-gated sodium channels are activated by binding of a ligand instead of a change in membrane potential.

Sodium Channel Isoform Specific Products:

Sodium Channel Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0432
    Propafenone
    		Inhibitor 99.93%
    Propafenone (SA-79), a sodium-channel blocker, acts an antiarrhythmic agent. Propafenone also has high affinity for the β receptor (IC50=32 nM). Propafenone blocks the transient outward current (Ito) and the sustained delayed rectifier K current (Isus) with IC50 values of 4.9 μm and 8.6 μm, respectively. Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction and induce apoptosis.
    Propafenone
  • HY-114237
    GDC-0276
    		Inhibitor 99.95%
    GDC-0276 is a potent, selective, reversible and orally active NaV1.7 inhibitor with an IC50 value of 0.4 nM. GDC-0276 is well tolerated and exhibits a good pharmacokinetic profile. GDC-0276 has the potential for the treatment of pain and to address shortcomings of existing pain medications, such as addiction and off-target side effects.
    GDC-0276
  • HY-B1167
    Ajmaline
    		Inhibitor 99.73%
    Ajmaline (Cardiorythmine) is a sodium channel blocking, class 1A anti-arrhythmic agent. Ajmaline blocks HERG currents with an IC50 of 1 μM in HEK cells and 42.3 μM in Xenopus oocytes. Ajmaline can be used for the research of the ventricular tachyarrhythmia.
    Ajmaline
  • HY-139346
    VX-150
    		Inhibitor 98.36%
    VX-150 is an orally active, highly selective NaV1.8 inhibitor. VX-150 has the potential for various pain indications research.
    VX-150
  • HY-107757
    GMQ
    		Activator 99.69%
    GMQ is a ASIC (acid-sensing ion) channel activator with an EC50 value of 1.83 mM for ASIC3 at pH 7.4. GMQ opens only ASIC3 but no other ASICs at pH 7.4. GMQ can be used for neurological disease research.
    GMQ
  • HY-A0082
    Diphenidol hydrochloride
    		Antagonist 99.95%
    Diphenidol hydrochloride (Difenidol hydrochloride) is a non-selective muscarinic M1-M4 receptor antagonist, has anti-arrhythmic activity. Diphenidol hydrochloride is also a potent non-specific blocker of voltage-gated ion channels (Na+, K+, and Ca2+) in neuronal cells. Diphenidol hydrochloride can be used in the study of antivertigo and antinausea.
    Diphenidol hydrochloride
  • HY-B0552A
    Dibucaine hydrochloride
    		Inhibitor 99.97%
    Dibucaine hydrochloride (Cinchocaine hydrochloride) is a sodium channel inhibitor. Dibucaine hydrochloride is a potent SChE inhibitor.
    Dibucaine hydrochloride
  • HY-155863
    AJ2-71
    		99.80%
    AJ2-71 is a SLCl5A4 inhibitor. AJ2-71 inhibits IFN-α production. AJ2-71 blocks SLC15A4-mediated MDP transport. AJ2-71 can be used for research of inflammation.
    AJ2-71
  • HY-B0653A
    Levobupivacaine hydrochloride
    		Inhibitor 99.98%
    Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local agent that can suppress or relieve pain. Levobupivacaine hydrochloride exerts agent that can suppress or relieve pain. and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
    Levobupivacaine hydrochloride
  • HY-P1604A
    ATX-II TFA
    		Modulator 99.84%
    ATX-II TFA is a specific Na+ channel Modulator toxin that can be isolated from the venom of sea anemone (Anemonia sulcata). ATX-II TFA causes delayed inactivation of the Na+
    ATX-II TFA
  • HY-112472
    S3969
    		Activator 98.38%
    S3969 is a potent and reversible activator of the human epithelial sodium channel (hENaC). The apparent EC50 for S3969 activation of hENaC is 1.2 μm.
    S3969
  • HY-125079
    DSP-2230
    		Inhibitor 98.33%
    DSP-2230 is a selective Nav1.7/Nav1.8 blocker, can be used to improve neuropathic pain.
    DSP-2230
  • HY-120669
    PF-06761281
    		Inhibitor 99.32%
    PF-06761281 (Compound 4a) is a potent, orally active, partial selective sodium-coupled citrate transporter (NaCT or SLC13A5) inhibitor with IC50 values of 0.51, 13.2 and 14.1 μM against HEKNaCT, HEKNaDC1 and HEKNaDC3, respectively.
    PF-06761281
  • HY-P1221A
    ProTx II TFA
    		Inhibitor 99.72%
    ProTx II TFA is a selective blocker of Nav1.7 sodium channels with an IC50 of 0.3 nM, and is at least 100-fold selective for Nav1.7 over other sodium channel subtypes. ProTx-II inhibits sodium channels by decreasing channel conductance and shifting activation to more positive potentials and blocks action potential propagation in nociceptors.
    ProTx II TFA
  • HY-118952A
    PF-06456384 trihydrochloride
    		Inhibitor 99.38%
    PF-06456384 trihydrochloride is a highly potent and selective NaV1.7 inhibitor with an IC50 of 0.01 nM. PF-06456384 trihydrochloride has the potential for formalin pain model research.
    PF-06456384 trihydrochloride
  • HY-112065
    PF-06869206
    		Inhibitor 99.88%
    PF-06869206 is an orally bioavailable selective inhibitor of the sodium-phosphate cotransporter NaPi2a (SLC34A1) with an IC50 of 380 nM.
    PF-06869206
  • HY-12533
    Disopyramide
    		Inhibitor 99.93%
    Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action.
    Disopyramide
  • HY-101350
    QX-314 bromide
    		Inhibitor
    QX-314 bromide is a membrane-impermeable permanently charged sodium channel blocker.
    QX-314 bromide
  • HY-B1704A
    Nisoxetine hydrochloride
    		Inhibitor 99.81%
    Nisoxetine hydrochloride is a potent and selective inhibitor of noradrenaline transporter (NET), with a Kd of 0.76 nM. Nisoxetine hydrochloride is an antidepressant and local anesthetic, it can block voltage-gated sodium channels.
    Nisoxetine hydrochloride
  • HY-126429
    Nav1.1 activator 1
    		Activator 99.89%
    Nav1.1 activator 1 (compound 4), a highly potent Nav1.1 activator with BBB penetration, increases decay time constant (tau) of Nav1.1 currents at 0.03 μM along with significant selectivity against Nav1.2, Nav1.5, and Nav1.6.
    Nav1.1 activator 1
Cat. No. Product Name / Synonyms Application Reactivity
Sodium Channel Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.